Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases
暂无分享,去创建一个
Ruili Huang | Narmada Thanki | Anders Wallqvist | D. Covell | Ruili Huang | Xiang-Jun Lu | A. Wallqvist | A. Rabow | N. Thanki | David G. Covell | Alfred A. Rabow | Xiang‐Jun Lu
[1] L. Liu,et al. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. , 2001, Biochemistry.
[2] M. Verstraete. Modulating platelet function with selective thrombin inhibitors. , 1996, Haemostasis.
[3] L. Iversen,et al. Hemostatic alterations in patients with benign and malignant colorectal disease during major abdominal surgery. , 2001, Thrombosis research.
[4] H. Forman,et al. Glutathione in defense and signaling: lessons from a small thiol. , 2002, Annals of the New York Academy of Sciences.
[5] P. Polčic,et al. Response of yeast to the regulated expression of proteins in the Bcl-2 family. , 2003, The Biochemical journal.
[6] K. H. Kalk,et al. Anaerobic enzyme⋅substrate structures provide insight into the reaction mechanism of the copper-dependent quercetin 2,3-dioxygenase , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Haddad. Recombinant human interleukin (IL)-1 beta-mediated regulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. , 2002, European cytokine network.
[8] D. Brömme,et al. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. , 2002, Current pharmaceutical design.
[9] M. V. Velzen,et al. Self-organizing maps , 2007 .
[10] Claus Jacob,et al. Reactive Sulfur Species: An Emerging Concept in Oxidative Stress , 2002, Biological chemistry.
[11] N. Davidson,et al. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. , 2003, Journal of Medicinal Chemistry.
[12] H. J. Woerdenbag,et al. Enhanced cytostatic activity of the sesquiterpene lactone eupatoriopicrin by glutathione depletion. , 1989, British Journal of Cancer.
[13] Y. Moriyama,et al. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. , 2000, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[14] U. Hübscher,et al. Colocalization of human Rad17 and PCNA in late S phase of the cell cycle upon replication block , 2002, Oncogene.
[15] B. Sjöberg,et al. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. , 1992, The Journal of biological chemistry.
[16] Keiji Tanaka,et al. The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome , 2003, The EMBO journal.
[17] C. Jacob,et al. Multiple roles of cysteine in biocatalysis. , 2003, Biochemical and biophysical research communications.
[18] R. Hargreaves,et al. Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[19] R. Hanson,et al. Inhibition of phosphofructokinase by quinone methide and alpha-methylene lactone tumor inhibitors. , 1970, Science.
[20] E. De Clercq,et al. A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. , 2001, Journal of medicinal chemistry.
[21] M. Uesugi,et al. Chemical genetic identification of the histamine H1 receptor as a stimulator of insulin-induced adipogenesis. , 2004, Chemistry & biology.
[22] J. Weinstein,et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.
[23] J. Buxbaum,et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.
[24] D. Botstein,et al. A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.
[25] Yingsheng Wang,et al. Iron chelator research: past, present, and future. , 2003, Current medicinal chemistry.
[26] R. White,et al. The mitogen‐activated protein (MAP) kinase ERK induces tRNA synthesis by phosphorylating TFIIIB , 2003, The EMBO journal.
[27] S. Cook,et al. Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. , 2003, The Biochemical journal.
[28] I. Schlichting,et al. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. , 1999, Journal of medicinal chemistry.
[29] G. Tucker. Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.
[30] D. Toft,et al. Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Bowman,et al. Role of hydrogen bonds in the reaction mechanism of chalcone isomerase. , 2002, Biochemistry.
[32] G L Snyder,et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.
[33] A. Butte,et al. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] Ha-won Jeong,et al. Antitumor effect of the cinnamaldehyde derivative CB403 through the arrest of cell cycle progression in the G2/M phase. , 2003, Biochemical pharmacology.
[35] G. Rishton. Reactive compounds and in vitro false positives in HTS , 1997 .
[36] P. Hajduk,et al. Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.
[37] J. Oxley,et al. p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy , 2002, BJU international.
[38] S. Courtneidge,et al. Src family tyrosine kinases and growth factor signaling. , 2000, Experimental cell research.
[39] Anders Wallqvist,et al. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data , 2003, Bioinform..
[40] Solomon H. Snyder,et al. Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[41] Yong Hae Kim,et al. Regioselective Alkylation and Arylation at the 6-Position of Pyrimidine: Synthesis of 5-Alkyl-6-arylmethyl-2,4-pyrimidinediones. , 1999 .
[42] J. Pouysségur,et al. Induction of Hypoxia-inducible Factor-1α by Transcriptional and Translational Mechanisms* , 2002, The Journal of Biological Chemistry.
[43] K. Ervin,et al. Development and application of fluorescence polarization assays in drug discovery. , 2003, Combinatorial chemistry & high throughput screening.
[44] A. Koong,et al. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. , 1994, Cancer research.
[45] Hui-Kang Wang. The therapeutic potential of flavonoids , 2000, Expert opinion on investigational drugs.
[46] R. Greil,et al. Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway. , 2003, Blood.
[47] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[48] H. Nawata,et al. High constitutive expression of heat shock protein 90α in human acute leukemia cells , 1992 .
[49] S. Bhattacharya,et al. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. , 1999, Genes & development.
[50] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[51] T. Krude,et al. Minichromosome replication in vitro: inhibition of re-replication by replicatively assembled nucleosomes. , 1994, The Journal of biological chemistry.
[52] A. Vollmar,et al. Ajoene, a compound of garlic, induces apoptosis in human promyeloleukemic cells, accompanied by generation of reactive oxygen species and activation of nuclear factor kappaB. , 1998, Molecular pharmacology.
[53] A. Wojtczak,et al. Comparison of binding interactions of dibromoflavonoids with transthyretin. , 2002, Acta biochimica Polonica.
[54] H. Zhang,et al. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. , 2001, Anticancer research.
[55] Yun-Jin Jung,et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[56] J. Adams,et al. Proteasome inhibitors as new anticancer drugs , 2002, Current opinion in oncology.
[57] K. Honikel,et al. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. , 1967, Biochimica et biophysica acta.
[58] Johan Auwerx,et al. Nuclear receptors and the control of metabolism. , 2003, Annual review of physiology.
[59] L. Pearl,et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.
[60] D. Shugar,et al. Acyclonucleoside Analogues Consisting of 5-and 5,6-Substituted Uracils and Different Acylic Chains: Inhibitory Properties vs Purified E. coli Uridine Phosphorylase , 1987, Zeitschrift fur Naturforschung. C, Journal of biosciences.
[61] D. Scudiero,et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. , 2002, Current topics in medicinal chemistry.
[62] S. Corey,et al. Src-related protein tyrosine kinases in hematopoiesis. , 1999, Blood.
[63] C. Coburn. Small-molecule direct thrombin inhibitors: 1997 - 2000 , 2001 .
[64] D. Sheehan,et al. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. , 2001, The Biochemical journal.
[65] J. Yodoi,et al. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation , 2002, Oncogene.
[66] S. Sheweita,et al. Cancer and phase II drug-metabolizing enzymes. , 2003, Current drug metabolism.
[67] J. Milner,et al. Allyl Sulfides Modify Cell Growth , 2000, Drug metabolism and drug interactions.
[68] D. Scudiero,et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.
[69] Jürgen Bajorath,et al. Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.
[70] B. Bowen,et al. Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. , 2003, Biochemical and biophysical research communications.
[71] George Morstyn,et al. Book Review: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval , 2004 .
[72] M. Ohno,et al. An Oxidized Purine Nucleoside Triphosphatase, MTH1, Suppresses Cell Death Caused by Oxidative Stress* , 2003, Journal of Biological Chemistry.
[73] J. Overgaard,et al. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. , 2000, The Journal of urology.
[74] M. D'Andrea,et al. Thrombin Regulation of Cell Function through Protease-Activated Receptors: Implications for Therapeutic Intervention , 2004, Biochemistry (Moscow).
[75] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[76] L. Fritz,et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.
[77] E. Fleck,et al. Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. , 2003, European journal of pharmacology.
[78] S. Kim,et al. Structural basis for chemical inhibition of CDK2. , 1996, Progress in cell cycle research.
[79] A. Koong,et al. Hypoxia Causes the Activation of Nuclear Factor κB through the Phosphorylation of IκBα on Tyrosine Residues , 1994 .
[80] Brian K Shoichet,et al. Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.
[81] D A Scudiero,et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.
[82] J. Whitney. Reference systems for kinase drug discovery: chemical genetic approaches to cell-based assays. , 2004, Assay and drug development technologies.
[83] P. Workman. Scoring a bull's-eye against cancer genome targets. , 2001, Current opinion in pharmacology.
[84] Gerhard Klebe,et al. Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.
[85] H. Gershon,et al. Antifungal activity of ring poly-chlorinated pyrimidines: structure activity relationships. , 1963, Applied microbiology.
[86] K. Michalek-Wagner,et al. Effects of Bleaching on Secondary Metabolite Chemistry of Alcyonacean Soft Corals , 2000, Journal of Chemical Ecology.
[87] H. Forman,et al. Glutathione in Defense and Signaling , 2002 .
[88] R. Eisenman,et al. Direct Regulation of RNA Polymerase III Transcription by RB, p53 and c-Myc , 2003, Cell cycle.
[89] L. Le Marchand. Cancer preventive effects of flavonoids--a review. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[90] J. Navarro,et al. Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. , 2001, Thrombosis research.
[91] C. Manesh,et al. Anti-tumour and anti-oxidant activity of naturally occurring isothiocyanates. , 2003, Journal of experimental & clinical cancer research : CR.
[92] Daniel Birnbaum,et al. DNA Arrays in Clinical Oncology: Promises and Challenges , 2003, Laboratory Investigation.
[93] J. Adams,et al. The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.
[94] M. Lerman,et al. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter , 2002, Journal of medical genetics.
[95] S. M. Kupchan,et al. Reactions of Alpha Methylene Lactone Tumor Inhibitors with Model Biological Nucleophiles , 1970, Science.
[96] D. Kleier,et al. Oxime Fungicides: Highly Active Broad-Spectrum Protectants , 1995 .
[97] Jae K. Lee,et al. Mining and Visualizing Large Anticancer Drug Discovery Databases , 2000, J. Chem. Inf. Comput. Sci..
[98] Kuo-ping Huang,et al. Glutathionylation of proteins by glutathione disulfide S-oxide. , 2002, Biochemical pharmacology.
[99] M. Laburthe,et al. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2 , 2001, British Journal of Cancer.
[100] G. D. Hunter,et al. Proteinase-activated receptors. , 2001, Pharmacological reviews.
[101] D. Wallwiener,et al. Statins can inhibit proliferation of human breast cancer cells in vitro. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[102] Ellen M. Langer,et al. Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage , 2002, Cell.
[103] R. Jerala,et al. Characterization of quercetin binding site on DNA gyrase. , 2003, Biochemical and biophysical research communications.
[104] U. Uhlin,et al. Structure and function of the radical enzyme ribonucleotide reductase. , 2001, Progress in biophysics and molecular biology.
[105] B. Chabner. Cancer Chemotherapy and Biotherapy: Principles and Practice (4th Edition) , 2006 .
[106] R. Raines,et al. Activation of the Prolyl Hydroxylase Oxygen-sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes* , 2003, Journal of Biological Chemistry.
[107] K. Jain,et al. Role of Proteomics in Diagnosis of Cancer , 2002, Technology in cancer research & treatment.
[108] J. Fahey,et al. Chemoprotection against cancer by phase 2 enzyme induction. , 1995, Toxicology letters.
[109] C. Supuran,et al. Cysteine-modifying agents: a possible approach for effective anticancer and antiviral drugs. , 2002, Environmental health perspectives.
[110] E. De Clercq,et al. Strategies in the design of antiviral drugs , 2002, Nature reviews. Drug discovery.
[111] S. Ramaswamy,et al. Structures of horse liver alcohol dehydrogenase complexed with NAD+ and substituted benzyl alcohols. , 1994, Biochemistry.
[112] K. Sletten,et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[113] K. Yamamoto,et al. Disassembly of Transcriptional Regulatory Complexes by Molecular Chaperones , 2002, Science.
[114] G. Bonfiglio,et al. Novel streptogramin antibiotics , 2001, Expert opinion on investigational drugs.
[115] Jeffrey W. Smith. Cilengitide Merck. , 2003, Current opinion in investigational drugs.
[116] R. Warnke,et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. , 1988, The New England journal of medicine.
[117] E. Sausville,et al. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. , 2002, Journal of medicinal chemistry.
[118] E. Skrzypczak‐Jankun,et al. Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 A reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. , 2003, International journal of molecular medicine.
[119] A. Habib,et al. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF‐1α , 2003, Journal of thrombosis and haemostasis : JTH.
[120] D. Vaux. Apoptosis and toxicology--what relevance? , 2002, Toxicology.
[121] G. Alonzo,et al. Investigations on organotin, organolead, lead(IV), and lead(II) dithiolates , 1985 .
[122] M. Jäättelä. Programmed cell death: many ways for cells to die decently , 2002, Annals of medicine.
[123] S. Kilfeather. 5-lipoxygenase inhibitors for the treatment of COPD. , 2002, Chest.
[124] D. Townsend,et al. The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.
[125] R. Hanson,et al. Inhibition of Phosphofructokinase by Quinone Methide and α-Methylene Lactone Tumor Inhibitors , 1970, Science.
[126] P. Workman,et al. HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.
[127] M. Salaspuro. Acetaldehyde, Microbes, and Cancer of the Digestive Tract , 2003, Critical reviews in clinical laboratory sciences.
[128] A. Lapthorn,et al. Plant glutathione transferases , 2002, Genome Biology.
[129] Martin Vogtherr,et al. NMR-based screening methods for lead discovery. , 2003, EXS.
[130] L. Neckers,et al. IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesis , 2003 .
[131] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[132] Z Chen,et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[133] S. Ramaswamy,et al. Structures of Horse Liver Alcohol Dehydrogenase Complexed with NAD+ and Substituted Benzyl Alcohols , 1994 .
[134] Giulio Rastelli,et al. Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. , 2003, Chemistry & biology.
[135] R. Kofler,et al. Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. , 2003, Biochimica et biophysica acta.
[136] S. Dedhar,et al. The role of integrin-linked kinase (ILK) in cancer progression , 2003, Cancer and Metastasis Reviews.
[137] C. Schofield,et al. Structure and mechanism of anthocyanidin synthase from Arabidopsis thaliana. , 2002, Structure.
[138] W. Patrick Walters,et al. Filtering databases and chemical libraries , 2004, Molecular Diversity.
[139] X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo). A model for the catalytic transition state. , 1975, The Journal of biological chemistry.
[140] M. Massiah,et al. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[141] H. Ariga,et al. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group. , 1989, The Journal of antibiotics.
[142] John N. Weinstein,et al. Mining the NCI Anticancer Drug Discovery Databases: Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues , 1998, J. Chem. Inf. Comput. Sci..
[143] H. Uramoto,et al. Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. , 2003, Acta biochimica Polonica.
[144] M. Laburthe,et al. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. , 2003, The American journal of pathology.
[145] A. Monks,et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. , 1996, Molecular pharmacology.
[146] Y. Fukuda,et al. Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung. , 2003, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.
[147] T. Olencki,et al. A Phase I Trial of Weekly Gemcitabine and Subcutaneous Interferon Alpha in Patients with Refractory Renal Cell Carcinoma , 2002, Investigational New Drugs.
[148] G. Powis,et al. Properties and biological activities of thioredoxins. , 2001, Annual review of biophysics and biomolecular structure.
[149] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[150] Richard A. Dixon,et al. Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase , 2000, Nature Structural Biology.
[151] S M Shortell,et al. Continuity of Medical Care: Conceptualization and Measurement , 1976, Medical care.
[152] L. del Peso,et al. The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen* , 2003, Journal of Biological Chemistry.
[153] M. Hollenberg,et al. International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors , 2002, Pharmacological Reviews.
[154] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[155] Michael Robert Wiley,et al. Small-molecule direct thrombin inhibitors , 1997 .
[156] L. Pearl,et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo , 1998, The EMBO journal.
[157] D A Scudiero,et al. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. , 1997, Anti-cancer drug design.
[158] Chrisostomos Prodromou,et al. The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N‐terminal domains , 2000, The EMBO journal.
[159] T. Myers,et al. Cytotoxic activities of Mannich bases of chalcones and related compounds. , 1998, Journal of medicinal chemistry.
[160] N. Sládek. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). , 2002, Cancer treatment and research.
[161] J. Verdebout,et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.
[162] S. Chu,et al. Pyrimidine acyclonucleosides, inhibitors of uridine phosphorylase. , 1981, Biochemical pharmacology.
[163] M. Sugantino,et al. Crystal structure of Vat(D): an acetyltransferase that inactivates streptogramin group A antibiotics. , 2002, Biochemistry.
[164] P. Pandolfi,et al. Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.
[165] F. Stickel,et al. Alcohol Consumption and Cancer of the Gastrointestinal Tract , 2006, Digestive Diseases.
[166] M. López-Lázaro. Flavonoids as anticancer agents: structure-activity relationship study. , 2002, Current medicinal chemistry. Anti-cancer agents.
[167] J. Adams. Potential for proteasome inhibition in the treatment of cancer. , 2003, Drug discovery today.
[168] H. Nawata,et al. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. , 1992, Leukemia research.
[169] B. Dijkstra,et al. Functional analysis of the copper-dependent quercetin 2,3-dioxygenase. 2. X-ray absorption studies of native enzyme and anaerobic complexes with the substrates quercetin and myricetin. , 2002, Biochemistry.
[170] Robert A. Weinberg,et al. Taking the Study of Cancer Cell Survival to a New Dimension , 2002, Cell.
[171] R. Meli,et al. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? , 2001, Biochemical pharmacology.
[172] G. Mulder,et al. GLUTATHIONE CONJUGATES AND THEIR SYNTHETIC DERIVATIVES AS INHIBITORS OF GLUTATHIONE-DEPENDENT ENZYMES INVOLVED IN CANCER AND DRUG RESISTANCE , 2002, Drug metabolism reviews.
[173] M. Monga,et al. Developmental Therapeutics Program at the NCI: molecular target and drug discovery process , 2002, Leukemia.
[174] N. Zhou,et al. DNA Damage-mediated Apoptosis Induced by Selenium Compounds* , 2003, Journal of Biological Chemistry.
[175] H. Pahl,et al. Inhibition of transcription factor NF-kappaB by sesquiterpene lactones: a proposed molecular mechanism of action. , 1999, Bioorganic & medicinal chemistry.
[176] R. Pike,et al. Inhibition of osteoblast apoptosis by thrombin. , 2003, Bone.
[177] A. Urbano,et al. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. , 2002, Biochemical pharmacology.
[178] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[179] T. Ideker,et al. A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.
[180] J. Dimmock,et al. Bioactivities of chalcones. , 1999, Current medicinal chemistry.
[181] Johannes H. Voigt,et al. Comparison of the NCI Open Database with Seven Large Chemical Structural Databases , 2001, J. Chem. Inf. Comput. Sci..
[182] H. Wang. Flavopiridol. National Cancer Institute. , 2001, Current opinion in investigational drugs.
[183] S. Baek,et al. 11-oxygenated cytotoxic 8,9-secokauranes from a New Zealand liverwort, Lepidolaena taylorii. , 1999, Phytochemistry.
[184] I. Kooter,et al. Functional analysis of the copper-dependent quercetin 2,3-dioxygenase. 1. Ligand-induced coordination changes probed by X-ray crystallography: inhibition, ordering effect, and mechanistic insights. , 2002, Biochemistry.
[185] D. Walsh,et al. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. , 2001, Archives of biochemistry and biophysics.
[186] E. Sausville,et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[187] S. Knapp,et al. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.
[188] Anders Wallqvist,et al. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. , 2002, Molecular cancer therapeutics.
[189] H. Pinedo,et al. Induction of Vascular Endothelial Growth Factor Expression and Hypoxia-inducible Factor 1α Protein by the Oxidative Stressor Arsenite* , 2001, The Journal of Biological Chemistry.
[190] L. Neckers. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. , 2003, Current medicinal chemistry.
[191] E. Middleton,et al. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. , 2000, Pharmacological reviews.
[192] J. G. Cory,et al. Effect of iron-chelating agents on inhibitors of ribonucleotide reductase. , 1981, Biochemical pharmacology.
[193] W. Skach,et al. Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation. , 2001, Biochemistry.
[194] T. Huang,et al. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin , 1994, British journal of haematology.
[195] N. Lawrence,et al. Cytotoxic michael-type amine adducts of α-methylene lactones alantolactone and isoalantolactone , 2001 .
[196] A. Konings,et al. Eupatoriopicrin-induced lipid peroxidation in liver and tumour tissue of the mouse. , 1989, Biochemical pharmacology.
[197] J. Buchner,et al. The Hsp90 complex--a super-chaperone machine as a novel drug target. , 1998, Biochemical pharmacology.
[198] W. Pratt,et al. Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.
[199] P. Kloetzel,et al. Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes* , 2003, Journal of Biological Chemistry.
[200] Spyros E. Zographos,et al. Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site* , 2000, The Journal of Biological Chemistry.
[201] M. Kunkel,et al. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs. , 1997, Anti-cancer drug design.
[202] W. S. Champney. Bacterial ribosomal subunit assembly is an antibiotic target. , 2003, Current topics in medicinal chemistry.
[203] M. Saraiva. Transthyretin mutations in hyperthyroxinemia and amyloid diseases , 2001, Human mutation.
[204] E. Clercq. Strategies in the design of antiviral drugs , 2010, Nature Reviews Drug Discovery.
[205] Roger L. Williams,et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.
[206] C. Kettner,et al. Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. , 1984, The Journal of biological chemistry.
[207] Khashayar Karimian,et al. Thiol-dependent enzymes and their inhibitors: a review. , 2002, Current medicinal chemistry.
[208] Michael R. Boyd,et al. The NCI In Vitro Anticancer Drug Discovery Screen , 1997 .
[209] K. Okkenhaug,et al. Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. , 2003, Archives of biochemistry and biophysics.